A new subcutaneous formulation of amivantamab shows high efficacy and improved safety for advanced NSCLC patients, enhancing treatment convenience.
Sun Min Lim, MD, PhD
Sun Min Lim, MD, PhD, is a professor at Yonsei University Cancer Center in Seoul, Republic of Korea.
Articles by Sun Min Lim, MD, PhD